Oppenheimer raised its price target on Chemed (NYSE: CHE) to $340.00 (from $315.00) while maintaining a Outperform rating.Analyst Michael Wiederhorn ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Chemed (CHE) PT Raised to $321 at RBC CapitalJuly 30, 2018 8:19 AM Chemed Corporation (CHE) Tops Q2 EPS by 4cJuly 25, 2018 4:23 PM Chemed Reports Second-Quarter 2018 Results - Earnings Guidance IncreasedJuly 25, 2018 4:15 PM